EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan

Hiroyuki Murota iD, Kazuhiko Arima iD, Takuo Yoshida iD, Hiroyuki Fujita iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Hiroyuki Murota und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nagasaki University School of Medical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Prurigo, Dermatitis, Atopic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prurigo nodularis (PN) is a chronic inflammatory skin disorder with a high disease burden. In this cross‐sectional, web‐based survey, Global Questions (GQ), the Numerical Rating Scales (NRS) for pruritus, burning sensation and sleep disturbance, the Short‐Form‐8 (SF‐8) Health Survey, Dermatology Life Quality Index (DLQI), Patient Health Questionnaire 9 (PHQ‐9), Work Productivity and Activity Impairment (WPAI), and Treatment Satisfaction Questionnaire for Medication–9 (TSQM‐9) scores were used to assess the current disease burden and treatment satisfaction among patients with PN in Japan. In total, 97 patients were included (55.7% male, median age 51 years, median duration of PN 36 months). Based on GQ scores, 35.1% of patients had mild disease, 50.5% moderate, and 14.4% severe disease. Disease burden increased as the severity of PN increased, as indicated by worsening of pruritus NRS scores and quality of life (DLQI, PHQ‐9, WPAI presenteeism, work productivity loss, and activity impairment scores). Patients with comorbid atopic dermatitis (AD) also had more intense pruritus than those without AD. Mean ± standard deviation TSQM‐9 scores for effectiveness, convenience, and global satisfaction were 54.7 ± 18.1%, 62.4 ± 15.2%, and 57.4 ± 15.9%, respectively. TSQM‐9 scores were lowest in patients receiving the most intensive guideline‐directed treatment (i.e., topical corticosteroids + systemic oral corticosteroids or cyclosporine), highlighting an unmet need for more effective treatment options for patients with PN. In summary, Japanese patients with PN reported increased disease burden and reduced treatment satisfaction with increased disease severity, despite the use of guideline‐recommended therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrurigoDermatitis, AtopicHumansMaleMiddle AgedFemaleQuality of LifeJapanCross-Sectional StudiesPatient SatisfactionPruritusCost of IllnessGlucocorticoidsChronic DiseasePersonal SatisfactionSeverity of Illness Index

Stichwörter der Autor:innen

burden of diseasecross-sectional studyprurigo nodularissurveys and questionnairestreatment satisfaction

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Dermatology, Nagasaki University School of Medical Sciences, Nagasaki, Japan.
  • Sanofi K.K., Tokyo, Japan.

ORCID-Profile: Hiroyuki Murota, Kazuhiko Arima, Takuo Yoshida, Hiroyuki Fujita

Förderung

  • Sanofi K.K.

Zitieren

APA

Murota, H., Arima, K., Yoshida, T., & Fujita, H. (2024). Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17045

Vancouver

Murota H, Arima K, Yoshida T, Fujita H. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17045

BibTeX
@article{Murota2024,
  author = {Murota, Hiroyuki and Arima, Kazuhiko and Yoshida, Takuo and Fujita, Hiroyuki},
  title = {Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17045}
}
Kostenlos starten →